Key result
Safflower seed extract reduces atherosclerotic lesion area by up to ~80% in mice.
Demonstrates LDL oxidation inhibition and reduced atherosclerosis in mice, suggesting dietary benefits.
The effects of defatted safflower seed extract and its phenolic constituents, serotonin derivatives, on atherosclerosis were studied. Ethanol-ethyl acetate extract of safflower seeds (SSE) inhibited low-density lipoprotein (LDL) oxidation induced in vitro by an azo-containing free-radical initiator V70 or copper ions. Two serotonin derivatives [N-(p-coumaroyl)serotonin, CS; N-feruloylserotonin, FS] and their glucosides were identified as the major phenolic constituents of the extract. The study with chemically synthesized materials revealed that a majority of the antioxidative activity of SSE was attributable to the aglycones of these two serotonin derivatives. Orally administered CS and FS suppressed CuSO(4)-induced plasma oxidation ex vivo. Long-term (15 week) dietary supplementation of SSE (1.0 wt %/wt) and synthetic serotonin derivatives (0.2-0.4%) significantly reduced the atherosclerotic lesion area in the aortic sinus of apolipoprotein E-deficient mice (29.2-79.7% reduction). The plasma level of both lipid peroxides and anti-oxidized LDL autoantibody titers decreased concomitantly with the reduction of lesion formation. Serotonin derivatives were detected as both intact and conjugated metabolites in the plasma of C57BL/6J mice fed on 1.0% SSE diet. These findings demonstrate that serotonin derivatives of SSE are absorbed into circulation and attenuate atherosclerotic lesion development possibly because of the inhibition of oxidized LDL formation through their strong antioxidative activity.
No takes yet. Share an insight, caveat, or question.
Koyama et al. (2006) studied Atherosclerosis. Safflower seed extract (SSE) and synthetic serotonin derivatives was evaluated on Atherosclerotic lesion area in the aortic sinus (29.2-79.7% reduction). Long-term (15-week) dietary supplementation with safflower seed extract and synthetic serotonin derivatives reduced the atherosclerotic lesion area in apolipoprotein E-deficient mice by 29.2-79.7%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: